US 11,732,036 B2
Antibody that binds to VEGF-A and ANG2 and methods of use
Roland Beckmann, Penzberg (DE); Sebastian Fenn, Penzberg (DE); Guido Hartmann, Basel (CH); Sabine Imhof-Jung, Penzberg (DE); Kristian Hobolt-Jensen, Penzberg (DE); Joerg Moelleken, Penzberg (DE); Michael Molhoj, Penzberg (DE); Christian Schantz, Penzberg (DE); Janina Speck, Penzberg (DE); Christoph Ullmer, Basel (CH); and Barbara Weiser, Penzberg (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 3, 2021, as Appl. No. 17/466,276.
Claims priority of application No. 20194610 (EP), filed on Sep. 4, 2020; and application No. 20209591 (EP), filed on Nov. 24, 2020.
Prior Publication US 2022/0073599 A1, Mar. 10, 2022
Int. Cl. C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01)
CPC C07K 16/22 (2013.01) [A61P 27/02 (2018.01); A61K 9/0019 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. An antibody or antigen binding fragment thereof that binds to human vascular endothelial growth factor A (VEGF-A) and to human angiopoietin-2 (ANG2), comprising a VH amino acid sequence of SEQ ID NO:19 and a VL amino acid sequence of SEQ ID NO:20.